Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlpha Growth Regulatory News (ALGW)

Share Price Information for Alpha Growth (ALGW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.25
Bid: 2.10
Ask: 2.40
Change: 0.05 (2.27%)
Spread: 0.30 (14.286%)
Open: 2.30
High: 2.30
Low: 2.25
Prev. Close: 2.20
ALGW Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Warrant Exercise and Total Voting Rights

15 Mar 2023 07:00

RNS Number : 9801S
Alpha Growth PLC
14 March 2023
 

 

Alpha Growth plc

("Alpha" or the "Company")

Exercise of Warrants, Issue of Equity for Expenses, and Total Voting Rights

Alpha Growth Plc (LSE: ALGW and OTCQB: ALPGF), a leading financial services specialist in the growing longevity asset class and insurance linked asset management, announces that it has received warrant exercise notices over an aggregate total of 18,750,000 ordinary shares of 0.1p each ("Ordinary Shares") in the Company for total consideration of £375,000.

In addition, the Company has issued 1,176,143 Ordinary Shares to certain advisers in lieu of expenses owed to them in relation to the Company's insurance business in 2022 at the closing price of 2.45p per Ordinary Share on 31 December 2022.

Application has been made for a total of 19,926,143 Ordinary Shares to be admitted to the standard listing segment of the Official List of the Financial Conduct Authority and to be admitted to trading on the main market for listed securities of the London Stock Exchange plc (together, "Admission"). Admission is expected to become effective at 8.00 a.m. on 20 March 2023.

Total Voting Rights

On Admission, the Company's issued share capital will consist of 451,813,531 Ordinary Shares. There are no Ordinary Shares held in treasury. Accordingly, the total number of voting rights in Alpha Growth plc at Admission will be 451,813,531.

The above figure 451,813,531 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Alpha Growth plc under the FCA's Disclosure Guidance and Transparency Rules.

** ENDS **

For more information, please visit www.algwplc.com or contact the following:

 

Alpha Growth plc

+44 (0) 20 3959 8600

Gobind Sahney, Executive Chairman

info@algwplc.com

 

Allenby Capital Limited

+44 (0) 20 3328 5656

Amrit Nahal (Sales and Corporate Broking)

Nick Athanas / Piers Shimwell (Corporate Finance)

 

UK Investor Relations - Mark Treharne

ir@algwplc.com

 

About Alpha Growth plc

Specialist in Longevity Assets

Alpha Growth plc is a financial advisory business providing specialist consultancy, advisory, and supplementary services to institutional and qualified investors globally in the multi-billion dollar market of longevity assets. Building on its well-established network, the Alpha Growth group has a unique position in the longevity asset services and investment business, as a listed entity with global reach. The group's strategy is to expand its advisory and business services via acquisitions and joint ventures in the UK and the US to attain commercial scale and provide holistic solutions to alternative institutional investors who are in need of specialised skills and unique access to deploy their financial resource in longevity assets.

Longevity Assets and Non-correlation

As a longevity asset, it is non-correlated to the real estate, equity capital and commodity markets. Its value is a function of time because as time passes the value gets closer to the face value of the policy. Hence creating a steady increase in the net asset value of the investment. This makes it highly attractive to investors wishing to counteract volatility within an investment portfolio and add yield.

Note: The Company only advises on and manages Longevity Assets that originate in the USA where the structured and life settlement market is highly regulated.

Forward Looking Statements Disclaimer

Certain statements, beliefs and opinions in this document are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Forward-looking statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward- looking statements, which speak only as of the date of this document. Readers should not treat the contents of this document as advice relating to legal, taxation or investment matters, and are to make their own assessments concerning these and other consequences, including the merits of information and the risks. Readers of this announcement are advised to conduct their own due diligence and agree to be bound by the limitations of this disclaimer.

Important Notice

The content of this announcement has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (FSMA). This announcement has been issued by and is the sole responsibility of the Company. The information in this announcement is subject to change.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDGGDXXGBDGXS
Date   Source Headline
10th Feb 20208:00 amRNSResult of AGM
31st Dec 20197:00 amRNSPublication of the 2019 Annual Report
17th Dec 20197:00 amRNSTrack Record Review, Placing & Total Voting Rights
2nd Dec 20197:00 amRNSAdvancement of Warehousing SPV and Subscription
11th Nov 20197:00 amRNSAppointments and Board changes
20th Sep 201911:46 amRNSSecond Price Monitoring Extn
20th Sep 201911:45 amRNSPrice Monitoring Extension
18th Sep 20193:31 pmRNSAlpha Growth - Holding(s) in Company
12th Aug 20197:00 amRNSHolding(s) in Company
15th Jul 20197:00 amRNSCorporate Update
2nd Jul 20199:14 amRNSHolding(s) in Company
5th Jun 20197:00 amRNSIssue of Equity & TVR
16th May 201912:00 pmRNSHolding(s) in Company
10th May 20192:16 pmRNSPublication of Prospectus
3rd May 201911:05 amRNSSecond Price Monitoring Extn
3rd May 201911:00 amRNSPrice Monitoring Extension
30th Apr 20197:20 amRNSProposed Placing
30th Apr 20197:00 amRNSBlackOak Alpha Growth Fund Launch
29th Apr 20194:00 pmRNSInterim Results
18th Apr 20192:00 pmRNSPrice Monitoring Extension
29th Mar 20192:28 pmRNSHolding(s) in Company
6th Mar 20197:00 amRNSBoard Changes
4th Mar 201910:10 amRNSResult of AGM
4th Mar 20197:00 amRNSCorporate Update
1st Mar 20197:00 amRNSAcquisition of Colva
20th Feb 201910:28 amRNSIssue of Equity
13th Feb 20197:00 amRNSAlpha Growth Investor Meeting
7th Feb 20197:00 amRNSAlpha Growth - Notice of Annual General Meeting
30th Jan 20197:00 amRNSAcquisition: Completion of ALM Acquisition
24th Dec 201810:52 amRNSFinal Results
21st Nov 20187:00 amRNSSL Investment Management Joint Venture
15th Nov 201811:36 amRNSHolding(s) in Company
24th Sep 20181:59 pmRNSHolding(s) in Company
17th Sep 20184:40 pmRNSSecond Price Monitoring Extn
17th Sep 20184:35 pmRNSPrice Monitoring Extension
17th Sep 20182:05 pmRNSSecond Price Monitoring Extn
17th Sep 20182:00 pmRNSPrice Monitoring Extension
17th Sep 201812:18 pmRNSHolding(s) in Company
17th Sep 20187:00 amRNSIssue of Equity and Director/PDMR Dealing
4th Sep 20185:14 pmRNSHolding(s) in Company
30th Aug 201812:16 pmRNSHolding(s) in Company
24th Aug 201812:59 pmRNSNotification of Major Holdings
18th Jul 20187:00 amRNSAcquisition of ALM
13th Jun 20187:00 amRNSHolding(s) in Company
8th Jun 20187:00 amRNSEngagement of Devonshire Warwick, Investor Event
1st Jun 20187:00 amRNSAppointment of Chief Operating Officer
11th May 20184:03 pmRNSHolding(s) in Company
30th Apr 20181:00 pmRNSInterim results
12th Mar 20182:13 pmRNSAppointment of Corporate Advisor and Broker
6th Feb 20187:00 amRNSLaunch of Innovative Hybrid Product

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.